



Clinician's guide to COVID-19 vaccination for patients with cancer

10th March 2022, Version 1.2

OFFICIAL

COVID-19 vaccines

Patients with malignancy are at increased risk for COVID-19 [1, 2]. Cases of COVID-19 in patients with haematological malignancy have been associated with high case fatality ratios of up to 60 per cent [2-4]. In addition, COVID-19 positive cancer patients experience more rapid deterioration, have more concurrent infections, have higher rates of intensive care unit admission and need for mechanical ventilation [1, 5].

Australia has secured four COVID-19 vaccines based on different platforms [6]. They are the Pfizer-BioNTech (Pfizer) vaccine (mRNA with lipid nanoparticle), AstraZeneca-Oxford ChAdOx1 (AstraZeneca) (non-replicating adenovirus vectored) vaccine, ModernaTX mRNA-1273 (Moderna) vaccine (mRNA) and Novavax NVX-CoV2373 (Novavax) (recombinant protein with adjuvant) vaccine.

COVID-19 vaccination in patients with cancer

Vaccination is an effective strategy to reduce risk and burden of infection in at-risk patients. However, in patients receiving treatment for malignancy, response to vaccination may be impaired due to patient, disease or treatment-related factors [7-13].

The Pfizer, AstraZeneca, Novavax and Moderna vaccines do not contain live SARS-CoV-2 and as such do not pose a risk of infection to recipients. Although the initial clinical trials of vaccines against SARS-CoV-2 have excluded patients receiving anti-cancer therapies, there are now multiple published studies evaluating the use and safety of COVID-19 vaccines in patients with cancer. Immunogenicity of COVID-19 vaccines in patients with cancer is highly variable. Studies suggest high immune response rates in patients with solid organ malignancies with responses comparable to patients without cancer[14]. However, response rates are significantly lower in patients with haematological malignancy, in particular patients receiving active therapy with anti-CD20 antibody therapies [15, 16]. Overall, vaccination associated adverse event rates are lower in patients with cancer[16]. Based on available studies, recent reports and guidance provided by the Australian Technical Advisory Group on Immunisation (ATAGI) [7, 17-25], the following broad principles for COVID-19 vaccination have been developed. Vaccination against COVID-19 is highly recommended.

Guidance for clinicians:

Vaccine type and response

- Patients with cancer are at higher risk for morbidity and mortality associated COVID-19 infection. Therefore, vaccination against COVID-19 is highly recommended.
- Carers and family members of patients with cancer are encouraged to keep up to date with their COVID-19 vaccination.
- Vaccines available in Australia do not contain live SARS-CoV-2, therefore do not pose an infectious risk to patients.

- Vaccine choice, number of doses and timing of vaccination should be guided by the latest ATAGI advice, taking into account patient age, community outbreaks of COVID-19, risks for severe complications from COVID-19 infection and possible vaccine related adverse events.
- Immune response to COVID-19 vaccination will likely be negatively impacted by underlying disease or therapy and patients should be advised to continue general measures such as hand hygiene, physical distancing and mask wearing. Early investigation of respiratory symptoms for SARS-CoV-2 and other respiratory viruses remain vital to guide need for antiviral therapies.

Adverse events

- Local adverse effect (e.g. pain) is the most common reported adverse effect following immunisation (AEFI).
- Fever is a less common adverse effect following vaccination. Persistent fever for more than 48 hours after vaccination (or fever in association with concerning symptoms (e.g. sweats, rigors) should prompt medical review and investigation for a cause including testing for COVID-19.
- A rare but serious adverse event, thrombosis with thrombocytopenia syndrome/vaccine-induced immune thrombotic thrombocytopenia, has been linked with use of the AstraZeneca-Oxford vaccine. New or persistent symptoms such as severe headache unresponsive to simple analgesia, beyond 3 days following vaccination should prompt medical review.
- A rare adverse event, myocarditis has been linked with the use of mRNA vaccines. Although rare, it is more likely to occur in the younger age groups. New symptoms such as chest pain within days of vaccination should prompt medical review.
- Radiation recall reactions have been noted in patients who have received radiotherapy prior to vaccination. These are usually mild. In addition to symptomatic management (analgesia and barrier creams), if this is suspected, please contact the treating radiation oncology team.
- A serious/severe immediate allergic reaction (e.g. anaphylaxis) to a COVID-19 vaccine or known component (such as polyethylene glycol [PEG] or polysorbate) is a contraindication to vaccination. PEG and polysorbate are also components in some conventional chemotherapeutic drugs (see Table 2 below). Referral for specialised review via the Victorian Specialist Immunisation Service is recommended. Patients should be assessed for whether they have subsequently tolerated other medications containing PEG or polysorbate before referral.

Serious or unexpected AEFI

- Clinics using CVMS
 - Record all medically attended AEFI in CVMS as an adverse event report –
 - Report will automatically be forwarded to SAEFVIC
Medically attended events are defined as a visit to general practitioner, emergency department, or hospital admission
 - If the adverse event is serious, IMMEDIATE notification is also required – see red box below
- Clinics not using CVMS
 - All medically attended AEFI to be reported to SAEFVIC via online reporting at www.saefvic.org.au or by using the QR code
 - Medically attended events are defined as a visit to general practitioner, emergency department, or hospital admission
 - If the adverse event is serious, IMMEDIATE notification is also required – see red box below
- Serious or unexpected AEFI require urgent direct notification in addition to routine reporting via CVMS or online [SAEFVIC form](http://www.saefvic.org.au).



Serious adverse events requiring urgent reporting

AEFI that result in:

- Transfer to hospital care
- CPR
- Defibrillator use
- Life-threatening incidents
- Death

1. Manage the AEFI by usual clinical pathways

2. Immediately notify via phone:

→ Business hours (Mon – Fri, 9AM – 5PM)
Call SAEFVIC **1300 882 924** (Option 1)

3. Submit an AEFI report online to [SAEFVIC](#)

Timing of vaccination

- Where possible, commence vaccination prior to anticipated commencement of myelosuppressive, lymphodepleting therapy or targeted therapies taking into account the need for and timing of subsequent vaccine dose(s).
- Delaying or interrupting cancer treatment/cycles to potentially improve responses to COVID-19 vaccination is not currently recommended.
- Where possible, avoid COVID-19 vaccination during anticipated periods of immune nadir (e.g. expected neutropenic nadir) or risk period for immune-related adverse event associated with the specific cancer therapy.
- Patients on dual checkpoint inhibitor therapy should discuss with their treating physician about the optimal timing of their COVID-19 vaccine in relation to their cancer therapy.
- If vaccinating during treatment, it would be preferable to vaccinate during the 'off' week during the treatment cycle to avoid potential overlap of treatment-related and vaccine-related adverse events.
- Defer vaccination if severe neutropenia present ($ANC < 0.5 \times 10^9/L$) until anticipated recovery.
- Patients have been able to mount an immune response to vaccination 3-6 months following autologous (as early as 2 months) and allogeneic haematopoietic stem cell transplant (HCT). Patients could be vaccinated from 3 months following HCT.
- Use of inactivated vaccines has not been associated with flares of graft vs. host disease (GvHD) and patients with stable GvHD on therapy could be vaccinated for COVID-19.
- Anti-CD20 antibody therapy is likely to negatively impact response to vaccination. However, with significant risk posed by COVID-19 it would be reasonable to vaccinate during or within 6-months of anti-CD20 with the understanding that protection maybe limited.

Special considerations

- Where possible, avoid COVID-19 vaccination on the same day as intravenous immunoglobulin replacement to minimise confusion around any adverse events.
- Currently, COVID-19 vaccines can be co-administered with the seasonal influenza vaccine. They can also be co-administered with other vaccines if required. However, interval administration of vaccines reduces the potential overlap of local and systemic side effects.
- If positron emission tomography (PET) scan is planned, discuss recommended timing of vaccination relative to PET scanning with their treating specialist and ensure receipt of recent vaccination is highlighted/communicated to the PET imaging team.
- Patients who have thrombocytopenia or on oral anticoagulants may develop a haematoma at the injection site. To minimise risk, application of prolonged pressure at injection site recommended.

- Suitability of vaccination in patients receiving end of life care should be evaluated in line with their goals of treatment/care.
- Avoid vaccination in a body area where a patient is receiving or has received radiation therapy to (e.g. use contralateral upper limb).

Safety and follow up

- Currently routine measurement of serological response to COVID-19 vaccination is not recommended as there is no established cut-off value which correlates with protection/response. Consider enrolling patient in available immunogenicity studies.
- Any suspected adverse event following immunisation should be reported to SAEFVIC, the state vaccine safety team based at the Murdoch Children’s Research Institute (MCRI), Parkville.

Table: Common drugs utilised in oncology containing PEG or polysorbate, adapted from Banerji et al.[26]

Common drugs used in oncology containing PEG		
PEG-filgrastim		
Trastuzumab		
Common drugs used in oncology containing polysorbate		
Anidulafungin	Durvalumab	Pembrolizumab
Atezolizumab	Elotuzumab	Ramucirumab
Avelumab	Etoposide	Rituximab (Truxima, Rituxan, Ruxience, Rituxan Hycela)
Bevacizumab	Fosaprepitant	Siltuximab
Belantamab	Inotuzumab	Temozolomide
Brentuximab	Ipilimumab	Tocilizumab
Cemiplimab	Isatuximab	Trastuzumab (Herceptin, Herceptin Hylecta, Herzuma, Herzuma, Kanjinti, Ontruzant, Trazimera)
Daratumumab	Mogamulizumab	Mycophenolate
Denosumab	Nivolumab	Peg filgrastim (Neulasta, Nyvepria, Udenyca)
Docetaxel	Ofatumumab (Kesimpta, Arzerra)	Filgrastim (Neupogen, Nivestym, Granix, Zarxio)

NB: This list is not exhaustive and monoclonal antibodies have been reported to cause immediate systemic symptoms which is not necessarily IgE mediated.

References

1. Liang, W., et al., *Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China*. *Lancet Oncol*, 2020.
2. Dai, M., et al., *Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak*. *Cancer Discov*, 2020. **10**(6): p. 783-791.
3. Shah, V., et al., *Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience*. *Br J Haematol*, 2020. **190**(5): p. e279-e282.
4. Cook, G., et al., *Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy*. *Br J Haematol*, 2020. **190**(2): p. e83-e86.
5. Dai, M., et al., *Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak*. *Cancer Discov*, 2020.
6. Health, A.D.o., *COVID-19 vaccines*. 2021.
7. Rubin, L.G., et al., *2013 IDSA clinical practice guideline for vaccination of the immunocompromised host*. *Clin Infect Dis*, 2014. **58**(3): p. e44-100.
8. Tomblyn, M., et al., *Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective*. *Biol Blood Marrow Transplant*, 2009. **15**(10): p. 1143-238.
9. (ATAGI), A.T.A.G.o.I., *The Australian immunisation handbook* A.G.D.o. Health, Editor. 2017, Australian Government Department of Health: Canberra.
10. Yri, O.E., et al., *Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment*. *Blood*, 2011. **118**(26): p. 6769-71.
11. Berglund, A., et al., *The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab*. *Acta Oncol*, 2014. **53**(9): p. 1212-20.
12. Bedognetti, D., et al., *Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens*. *J Immunol*, 2011. **186**(10): p. 6044-55.
13. Ide, Y., et al., *Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies*. *Hum Vaccin Immunother*, 2014. **10**(8): p. 2387-94.
14. Oosting, S.F., et al., *mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial*. *Lancet Oncol*, 2021. **22**(12): p. 1681-1691.
15. Becerril-Gaitan, A., et al., *Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis*. *Eur J Cancer*, 2022. **160**: p. 243-260.
16. Teh, J.S.K., et al., *Immunogenicity of COVID-19 vaccines in patients with hematological malignancy: a systematic review and meta-analysis*. *Blood Adv*, 2021.
17. Engelhard, D., et al., *European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN*. *Transpl Infect Dis*, 2013. **15**(3): p. 219-32.
18. Teh, B.W., et al., *A randomised trial of two 2-dose influenza vaccination strategies for patients following autologous haematopoietic stem cell transplantation*. *Clin Infect Dis*, 2020.
19. BW, T., *Vaccination Schedules*. *Infection Management in Hematology*, ed. M.H. Oliver Cornely. 2020: Springer.
20. Rieger, C.T., et al., *Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)*. *Ann Oncol*, 2018. **29**(6): p. 1354-1365.
21. Ullmann, A.J., et al., *Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016*. *Ann Hematol*, 2016. **95**(9): p. 1435-55.
22. Immunisation, A.T.A.G.o., *ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns*, A.D.o. Health, Editor. 2021.
23. Soyfer, V., et al., *COVID-19 Vaccine-Induced Radiation Recall Phenomenon*. *Int J Radiat Oncol Biol Phys*, 2021.
24. Greinacher, A., et al., *Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination*. *N Engl J Med*, 2021.
25. Schultz, N.H., et al., *Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination*. *N Engl J Med*, 2021.

26. Banerji, A., et al., *mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach*. *J Allergy Clin Immunol Pract*, 2021. **9**(4): p. 1423-1437.